Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients
Language English Country Switzerland Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
34034261
DOI
10.1159/000515806
PII: 000515806
Knihovny.cz E-resources
- Keywords
- Disease activity, Multiple sclerosis, Neurofilament light chain, No evident disease activity,
- MeSH
- Biomarkers MeSH
- Intermediate Filaments MeSH
- Humans MeSH
- Magnetic Resonance Imaging MeSH
- Brain MeSH
- Multiple Sclerosis, Relapsing-Remitting * MeSH
- ROC Curve MeSH
- Multiple Sclerosis * diagnostic imaging MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biomarkers MeSH
INTRODUCTION: There is a need for blood biomarkers of disease activity in multiple sclerosis (MS). The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept three-domain no evident disease activity (NEDA-3). METHODS: Levels of pNfL (SIMOA) were examined in 159 MS patients and analyzed in relationship to NEDA-3 status (absence of relapse, disability score worsening, and brain magnetic resonance activity) during the last 12 months. The accuracy of the proposed model was evaluated by calculating the area under the receiver operating characteristics (ROC) curve. From the pNfL cutoff, we evaluated the NEDA-NfL status (no relapse, no Expanded Disability Status Scale [EDSS] worsening, and pNfL below the cutoff value). RESULTS: Levels of pNfL were significantly higher in MS patients than in healthy controls (p < 0.001). From a total of 159 patients, 80 (50.3%) achieved NEDA-3 status, while 79 (49.7%) patients showed evident disease activity (EDA) status. pNfL were significantly lower in the NEDA-3 group than in the EDA group (pNfL mean 7.06 pg/mL [standard deviation (SD) 2.37] vs. pNfL mean 13.04 pg/mL [SD 7.07]) (p < 0.001). ROC analysis showed that pNfL predicts NEDA-3 status (sensitivity and specificity were 80.5 and 72.7%, respectively, p < 0.001), and NEDA-NfL predicts NEDA-3 status (sensitivity and specificity were 97.1 and 82.9%, respectively, p < 0.001). CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA status in patients with MS and could be an alternative to brain magnetic resonance investigation.
AXON Neuroscience R and D Services SE Bratislava Slovakia
Department of Medical and Clinical Biochemistry Pavol Jozef Šafárik University Košice Slovakia
Department of Neurology Pavol Jozef Šafárik University Košice Slovakia
Department of Neurology University Hospital L Pasteur Košice Košice Slovakia
Department of Social and Behavioral Medicine Pavol Jozef Šafárik University Košice Slovakia
Institute of Neuroimmunology Slovak Academy of Sciences Bratislava Slovakia
Olomouc University Social Health Institute University Palacky Olomouc Czechia
References provided by Crossref.org